INmune Bio Q2 EPS $(0.36) Beats $(0.40) Estimate, Sales $46.00K Up From $16.00K YoY
Portfolio Pulse from Benzinga Newsdesk
INmune Bio (NASDAQ:INMB) reported Q2 losses of $(0.36) per share, beating the analyst consensus estimate of $(0.40) by 10 percent. This is a 5.26 percent increase over losses from the same period last year. The company also reported $46.00 thousand in sales, a 187.50 percent increase from last year.
August 07, 2023 | 8:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INmune Bio reported better than expected Q2 results, with losses per share lower than estimates and a significant increase in sales YoY.
INmune Bio reported better than expected Q2 results, with losses per share lower than estimates and a significant increase in sales YoY. This could potentially lead to a positive market reaction, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100